Search results

If a RCT trial demonstrates a 30 or 50% decrease in fatigue for Abilify that would be huge and would almost certainly earn Abilify a prescribable (sp) indication for MECFS. And would be fantastic for patients! So my opinion is that this should be among the highest priority areas of research...

yes it is—like here for example. https://www.depressionforums.org/forums/topic/78550-abilify-has-it-stopped-working-or-do-i-need-a-higher-dose/

Correct—I agree. Which is why I was put-off by the somewhat overly-critical sentiment coming from this thread about a med originally developed for psychiatric conditions that might be repurposed for MECFS. Fine to criticize the shortcomings of the published study. But not fine to criticize the...

This first comment on that Reddit thread points out the problem of tolerance and how s/he overcame it.

This is the second partial dopamine agonist study in two days—the first was this one https://www.s4me.info/threads/open%E2%80%90label-study-with-the-monoamine-stabilizer-%E2%80%90-%E2%80%90osu6162-in-myalgic-encephalomyelitis-chronic-fatigue-syndrome-haghighi-et-al-2021.18971/ Also there are...

Dear @Hutan I honestly think you are being overly critical here...~50% reduction in fatigue and brain fog is pretty significant.... But this is your opinion...it is not mine. There are several patient reports of people going from severe/very severe (like bed bound in dark rooms) to moderate...

To clarify a bit, the Abilify itself causes weight gain—this is a side effect.

An alternative explanation is that aripiprazole is actually effective at treating the symptoms of MECFS. Authors don’t claim this a RCT study. Weight gain is a side effect of antipsychotics so actually surprised weight gain was rather low.

The main challenge will be how to overcome tolerance/tachyphlaxis/ poop-out.

Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole...

OSU 6162 is a partial D2 agonist similar to Abilify. Probably something here. Would like to see a longer study to see if tolerance/tachyphlaxis develops. https://en.m.wikipedia.org/wiki/OSU-6162

Silent no more...

Senior author https://en.m.wikipedia.org/wiki/Eric_Schadt

A lot of work just to make the visualization animations.

I’m waiting for my @Simon M explainer....Didn’t know that Mt.Sinai had a group working on this.

We’re druggable! Also too early in the process for them to cover Abilify. First I’ve heard of Myelophil. https://www.frontiersin.org/articles/10.3389/fphar.2019.00991/full

I support OMF—with many researchers and centers they are most likely to make a breakthrough.

Review article.

Moved post Whitney not sleeping well due to Abilify.